Search research articles
Contact Us
Filters
Showing results (31-40 of 53) with videos related to
Page
of 6
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2012
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
P Dubsky, M Filipits, R Jakesz, et al.
The Lancet. Oncology
|
February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Reinhard Dummer, Jan C Brase, James Garrett, et al.
British Journal of Cancer
|
October 26, 2013
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients
P Dubsky, J C Brase, R Jakesz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 28, 2011
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy
Sarah Minner, Malaika Enodien, Hüseyin Sirma, et al.
Breast Cancer Research and Treatment
|
February 25, 2016
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
Miguel Martin, Jan C Brase, Amparo Ruiz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2019
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial
M H Kulke, P Ruszniewski, E Van Cutsem, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial
M H Kulke, P Ruszniewski, E Van Cutsem, et al.
Nature Medicine
|
October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade
P Nuciforo, T Pascual, J Cortés, et al.
Cancer Research Communications
|
March 21, 2025
The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Benjamin J Solomon, Daniel S W Tan, Gilberto de Castro, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 53) with videos related to
Sort By:
Page
of 6
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2012
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
P Dubsky, M Filipits, R Jakesz, et al.
The Lancet. Oncology
|
February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Reinhard Dummer, Jan C Brase, James Garrett, et al.
British Journal of Cancer
|
October 26, 2013
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients
P Dubsky, J C Brase, R Jakesz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 28, 2011
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy
Sarah Minner, Malaika Enodien, Hüseyin Sirma, et al.
Breast Cancer Research and Treatment
|
February 25, 2016
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
Miguel Martin, Jan C Brase, Amparo Ruiz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2019
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial
M H Kulke, P Ruszniewski, E Van Cutsem, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial
M H Kulke, P Ruszniewski, E Van Cutsem, et al.
Nature Medicine
|
October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade
P Nuciforo, T Pascual, J Cortés, et al.
Cancer Research Communications
|
March 21, 2025
The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Benjamin J Solomon, Daniel S W Tan, Gilberto de Castro, et al.
Page
of 6